Turkey Tail Mushroom

Trametes versicolor (Turkey Tail) extract, specifically PSK, for humans, the most commonly used dose of Trametes versicolor (Turkey Tail) extract, specifically PSK, in clinical studies and practice is 3 grams per day, often divided into multiple doses . This dosage has been used as an adjunct to conventional cancer treatment and is associated with improved survival outcomes . Doses up to 9 grams per day have been used in Japan. The provided results do not specify a standard dose for animals within a cancer protocol. While one of the user's initial notes mentions 100 mg/kg (divided 2–3 times daily), this specific dosage and its application are not confirmed. General toxicological assessments indicate that PSK and PSP have low toxicity in animals.

Artemisinin / Artesunate Pharmacy (sweet wormwood supplements) or compounded -

Oral artemisinin 5–15 mg/kg/day. For humans, the only randomized, double-blind, placebo-controlled trial of artesunate in cancer used a dose of 200 mg of oral artesunate daily for 14 days . Other sources suggest that artemisinin-based drugs are being reviewed for their potential to improve cancer outcomes, but specific standard dosing regimens beyond this trial are not detailed. For animals, studies have used varying doses. In an animal model of stage II breast cancer, comparative studies were conducted on artemisinin, artesunate, and artemether, though exact dosages for this study are not specified. Another in vivo study used dosages ranging from 50 to 100 mg/kg/day of artemisinins, which showed little toxicity. In dogs with cancer, artesunate was administered at 950 mg divided into two daily doses (median effective dosage of 651 mg/m²) during days 1-85, later reduced to 800 mg per day. To minimize toxicities, a maximum dosage of 1200 mg/m² has been recommended in some canine studies. One rat study involved administering 3.5 mg/kg of artesunate once daily for four weeks.

Fenbendazole or Mebandazole (very similar chemical)

For humans, there is no established standard dose for fenbendazole or mebendazole in cancer treatment as their use is not FDA-approved for this purpose and clinical trial data is limited. However, based on anecdotal reports and repurposed protocols often discussed in integrative oncology circles, a common regimen cited involves mebendazole at 100–200 mg twice daily for three consecutive days per week (e.g., 3 days on, 4 days off), sometimes cycled over several weeks. One case report mentioned the use of fenbendazole at 1 g (1000 mg) taken orally once daily, combined with dietary changes and supplements, though this is not part of a standardized clinical protocol. For animals, fenbendazole is commonly used as an anthelmintic. A typical deworming dose in dogs and cats is 50 mg/kg orally once daily for three consecutive days. This "3 days on, 4 days off" schedule aligns with some repurposed cancer protocols observed in veterinary settings, particularly in canine cancer management, where it has been used off-label. For example, doses of fenbendazole ranging from 22.7 to 50 mg/kg/day for 3–5 days have been reported in dogs. Mebendazole has also been used in animals, though specific anti-cancer dosing in veterinary oncology is less well-documented.

Ivermectin

For humans, the antiparasitic dose of ivermectin is typically 150–200 µg/kg as a single oral dose. However, some preclinical studies suggest that higher doses may be required for anticancer effects, potentially exceeding standard antiparasitic dosing. A phase I clinical trial in cancer patients explored escalating doses of ivermectin from 30 to 90 mg weekly (equivalent to approximately 0.4–1.2 mg/kg for a 75 kg person), finding that doses up to 60 mg were well tolerated and achieved plasma concentrations associated with antitumor activity in vitro. This suggests that anticancer use may require prolonged low-dose administration or higher-than-standard parasitic doses, though such regimens remain investigational. For animals, ivermectin is widely used in veterinary medicine at species-specific doses. In dogs, the typical dose ranges from 6 to 12 µg/kg daily or every other day for parasite control (e.g., heartworm prevention), while much higher doses (up to 600 µg/kg) have been used in certain conditions like demodicosis under veterinary supervision. However, breeds with MDR1 gene mutations (e.g., Collies, Australian Shepherds) are highly sensitive to neurotoxicity at elevated doses. In rodent models, ivermectin has been administered at 0.2–0.4 mg/kg intraperitoneally or orally to evaluate antitumor effects. Despite promising in vitro data, there is limited published evidence on standardized anticancer dosing protocols in companion animals.

• Toceranib (first choice if obtainable)Palladia tablets25–32.5 mg EOD (2.5–3.25 mg/kg)Highest published ORR/SD rates across histologies
• Verdinexor (lymphoma/round-cell)Laverdia tablets10–15 mg twice weekly (with food)Conditional approval; oral convenience
• Chlorambucil (metronomic, any solid tumor)Compounded capsules0.4–0.8 mg/kg dailyProspective canine data; low toxicity
• Cyclophosphamide (metronomic alternative)Compounded capsules1–2.5 mg/kg daily (± furosemide)Multiple supportive studies; monitor bladder
• Imatinib (Gleevec)BCR-ABL TKIChronic myeloid leukemia (CML), GISTCML: ~98% complete cytogenetic response; 10-year OS >85% in chronic phase. Essentially turned CML into a chronic disease.400–800 mg dailyGold standard for CML; resistance via T315I mutation led to newer TKIs (dasatinib, nilotinib, ponatinib).
• Osimertinib (Tagrisso)EGFR TKI (3rd-gen)NSCLC with EGFR exon 19del or L858R; adjuvant after resectionFirst-line: PFS 18.9 mo vs 10.2 mo (gefitinib/erlotinib); OS benefit. Brain penetration excellent.80 mg dailyCurrent first-line standard for EGFR-mutant NSCLC; overcomes T790M resistance.
• Ibrutinib (Imbruvica) / Acalabrutinib (Calquence) / Zanubrutinib (Brukinsa)BTK inhibitorsCLL/SLL, mantle cell lymphoma, WaldenströmCLL: PFS >80% at 5–7 years (especially with obinutuzumab). High response rates in relapsed disease.Ibrutinib 420–560 mg dailyTransformed CLL management; cardiac toxicity (afib) higher with ibrutinib → shift to acala/zanu.Capecitabine (Xeloda)Oral fluoropyrimidine (prodrug of 5-FU)Breast (metastatic), colorectal (adjuvant/metastatic)Equivalent to IV 5-FU/LV in CRC (PFS/OS similar); convenient for metastatic breast after anthracyclines/taxanes.1250 mg/m² BID ×14d q21dHand-foot syndrome common; DPD deficiency testing recommended (severe toxicity risk).Lenalidomide (Revlimid)Immunomodulatory (IMiD)Multiple myeloma, MDS (del5q), follicular/marginal zone lymphomaMyeloma maintenance: PFS doubled post-transplant; ORR >90% with dexamethasone.10–25 mg daily (21/28d cycles)Standard in myeloma; thrombosis risk → mandatory anticoagulation.Olaparib (Lynparza) / Rucaparib (Rubraca)PARP inhibitorsOvarian, breast, pancreatic, prostate (BRCA-mut)Ovarian maintenance: PFS 56 mo vs 13 mo (placebo) in BRCA-mut.Olaparib 300 mg BIDLandmark for HRD cancers; anemia common.Sunitinib (Sutent) / Pazopanib (Votrient)Multi-TKI (VEGFR etc.)Renal cell carcinoma (RCC), GIST (post-imatinib)RCC first-line: PFS ~11 mo; OS benefit historically.Sunitinib 50 mg daily (4/2 schedule)Fatigue, hypertension, hand-foot common; largely replaced by IO combos.Regorafenib (Stivarga) / Fruquintinib (Fruzaqla)Multi-TKIRefractory metastatic CRC, HCC (post-sorafenib)CRC: OS 6.4 mo vs 5 mo (placebo); modest but approved in last-line.Regorafenib 160 mg daily (21/28d)Hand-foot, fatigue limit tolerability.Enzalutamide (Xtandi) / Abiraterone (Zytiga)Androgen pathwayProstate cancer (mHSPC, nmCRPC, mCRPC)mCRPC pre-chemo: OS ~35 mo; now standard in earlier settings.Enzalutamide 160 mg dailyHypertension/seizures (enza); requires prednisone (abi).Palbociclib (Ibrance) / Ribociclib (Kisqali) / Abemaciclib (Verzenio)CDK4/6 inhibitorsHR+ HER2– advanced breast cancer (+ endocrine therapy)First-line: PFS doubled (~25–28 mo); OS benefit confirmed.

MebendazoleAntiparasitic (pharmacy)Microtubule disruption, anti-angiogenesisPhase I/II trials (glioma, CRC): some stable disease; case reports of responses in refractory cancers. Synergistic with chemo in preclinical.Best-studied benzimidazole; ongoing trials (e.g., with temozolomide in glioma).FenbendazoleVeterinary antiparasitic (not human-approved)Similar to mebendazole (tubulin binding)Anecdotal case reports/social media (e.g., "Joe Tippens" protocol); no formal human trials. Preclinical activity in multiple lines.Not licensed for humans; purity/safety concerns with vet products.IvermectinAntiparasitic (pharmacy)Inhibits importin α/β (nuclear transport), WNT pathway, induces apoptosisRetrospective analyses of cancer patients on ivermectin for parasites show mixed outcomes; early-phase trials ongoing (breast, leukemia). No proven benefit in RCTs.High doses needed for anticancer effect may be toxic; misinformation common.MetforminDiabetes drug (pharmacy)AMPK activation, mTOR inhibition, reduces insulin/IGF-1Observational: reduced cancer incidence/risk in diabetics; adjuvant trials (breast, prostate) show modest PFS benefit in some subgroups. No definitive survival gain yet.Safest/most studied; large ongoing RCTs (e.g., MA.32 breast).